The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck Joins With Chinese Distributor On Weight Loss Pill
( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...
Merck’s weight-loss pill deal: what it means for Eli Lilly
Merck announces a $2.0 billion agreement with Hansoh Pharma. The deal gives it rights to Hansoh's experimental weight-loss ...
Seeking Alpha6d
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
However, Wall Street was unmoved, with Bernstein analyst Courtney Breen noting that HS-10535 will likely trail Lilly's (LLY) ...
Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock. Rising maternal ...